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ABSTRACT
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurodege-
nerative disorder characterized by late-infantile onset spastic ataxia and other neurological 
features. ARSACS has a high prevalence in northeastern Quebec, Canada. Several ARSACS 
cases have been reported outside Canada in recent decades. This is the first report of 
typical clinical and neuroimaging features in a Brazilian family with probable diagnosis 
of ARSACS. 
Key words: autosomal recessive spastic ataxia of Charlevoix-Saguenay, early onset spastic 
ataxia.
Ataxia espástica autossômica recessiva de Charlevoix-Saguenay (ARSACS): aspectos 
clínicos e de neuroimagem típicos em uma família brasileira
RESUMO
A ataxia espástica autossômica recessiva de Charlevoix-Saguenay (ARSACS) é doença 
degenerativa do sistema nervoso, caracterizada por ataxia associada a espasticidade, entre 
outras manifestações neurológicas, de início na infância. A doença tem alta prevalência 
na região de Quebec, no Canadá. Muitos relatos de ARSACS têm sido descritos fora do 
Canadá nas últimas décadas. Nesse artigo, relatamos a primeira descrição dos aspectos 
clínicos e de neuroimagem típicos em uma família brasileira com provável diagnóstico 
de ARSACS. 
Palavras-chave: ataxia espástica autossômica recessiva de Charlevoix-Saguenay, ataxia 
e espasticidade na infância.
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Autosomal recessive spastic ataxia of 
Charlevoix-Saguenay (ARSACS) is an in-
herited neurodegenerative disorder char-
acterized by early onset spastic ataxia, dys-
arthria, nystagmus, distal muscle wasting, 
finger and foot deformities, mixed sen-
sorimotor neuropathy and retinal hyper-
myelination. It was originally described 
in the late 1970s, with a high prevalence 
among inhabitants of Charlevoix-Sa-
guenay, northeastern Quebec, Canada1-3. 
ARSACS is due to mutations in a large 
single exon gene encoding a novel protein 
called sacsin that contains a heat-shock 
domain, which suggests that it subserves 
chaperone function4. In recent years sev-
eral cases have been described in coun-
tries other than Canada2,5 but in spite of 
that this disease remains underdiagnosed 
outside Canada5. Therefore, we highlight 
the approach of patients presenting with 
late-infantile onset of ataxia and spasticity. 
The aim of this article is to describe a 
Brazilian family of three siblings of non-
Arq Neuropsiquiatr 2011;69(2-B)
 289
Charlevoix-Saguenay ataxia
Pedroso et al.
consanguineous parents with clinical picture and brain 
magnetic resonance imaging consistent with the diag-
nosis of ARSACS. 
METHOD
The three patients were seen at the Division of Gen-
eral Neurology and Cerebellar Ataxia, Department of 
Neurology and Neurosurgery of São Paulo Hospital, 
Universidade Federal de São Paulo, in São Paulo, Brazil. 
Their first visit was in January 2010 and they have been 
under diagnostic investigation since then. 
All patients gave written informed consent to have 
their case presented in this article and approved its pub-
lication in medical literature. 
Cases description
The patients were born in the city of Taubaté, state of 
São Paulo, southeastern Brazil. Their father is originally 
from the city of Itajubá, state of Minas Gerais and their 
mother from the city of Lorena, state of São Paulo. Their 
parents have not blood relatives and there is no family 
history of neurological disease. The children are three sib-
lings of nonconsanguineous parents, and are all affected 
by the disease (Fig 1). There is no other affected family 
member in the family background. We did not identify any 
consanguineous marriages in other family members. The 
three patients were examined together in the first visit. 
Patient 1 – Sibling 1 is a 31-year-old woman who 
was first evaluated in January 2010. She presented to 
our clinic with late-infantile onset of low progressive 
difficulty walking and slurred speech that started at 
the age of 12 months. Her brother and sister had the 
same symptoms. She was still able to walk in spite of 
the long disease duration. On neurological examina-
tion, she had cerebellar ataxia, severe spasticity in lower 
limbs, global hyperreflexia, dysarthria, pes cavus (Fig 2), 
distal amyotrophy of the limbs and nystagmus. Her cog-
nitive function was normal. Electroneuromyography 
showed sensorial and motor axonal peripheral neurop-
athy. Ophthalmologic evaluation was normal. Magnetic 
resonance imaging (MRI) revealed atrophy of the cere-
bellum, mainly in the superior vermis, and linear hypoin-
tensities in T2 and FLAIR weighted images in the pons 
(Fig 3). Previous investigations in other clinics showed 
negative genetic test for Friedreich’s ataxia, normal vi-
tamin E status and negative molecular tests for spinocer-
ebellar ataxias (SCA) type 1, 2 and 3. She was started on 
baclofen 30 mg daily for spasticity and physical rehabil-
itation program. She was evaluated again three months 
later with mild improvement of spasticity.
Fig 3. Sagittal T1-weighted MRI [A, B and C] 
showing significant atrophy of the superior 
vermis in all patients. There is also marked 
atrophy of the cervical spinal cord in the 
three patients. Axial FLAIR-weighted MRI [D, 
E and F] showing similar linear hypointensi-
ties in all patients.
Fig 1. Heredogram show ing three 
affected siblings of nonconsan-
guineous parents.
Fig 2. Pes cavus and 
hammer toes in Pa-
tient 1.
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Patient 2 – A 30-year-old man who also came to our 
clinic on the same date, presenting with late-infantile 
onset of low progressive difficulty walking and slurred 
speech that also started at the age of 12 months. He had 
similar clinical features on examination, but less severe 
than Patient 1: cerebellar ataxia, spasticity, global hyper-
reflexia, dysarthria, pes cavus, distal amyotrophy of the 
limbs and nystagmus. His cognitive function was also 
normal. Ophthalmologic evaluation was normal. Brain 
MRI showed similar findings: atrophy of the cerebellum, 
mainly in the superior vermis, and linear hypointensities 
in T2 and FLAIR weighted images in the pons (Fig 3). He 
was started on a combination of baclofen 30 mg daily and 
cyclobenzaprine 10 mg daily, and physical rehabilitation. 
Three months later he reported mild symptom improve-
ment and mild reduction in spasticity with medication.
Patient 3 – A 26-year-old woman who presented 
to our clinic on the same date with late-infantile onset 
of low progressive mild difficulty walking and slurred 
speech that started at the age of 12 months. On neuro-
logical examination, the same features reported in the 
first two cases were seen: cerebellar ataxia, spasticity, 
global hyperreflexia, dysarthria, pes cavus, and nys-
tagmus. There was no amyotrophy of lower limbs and 
her cognitive function was also normal. Ophthalmologic 
evaluation was normal. Brain MRI showed similar find-
ings as for Patients 1 and 2: cerebellar atrophy, mainly 
in the superior vermis, and linear hypointensities in T2 
and FLAIR images in the pons (Fig 3). She opted for not 
taking any medication. 
DISCUSSION
ARSACS was first described in 1978 as a recessive 
form of spastic ataxia in Quebec, Canada. Although the 
vast majority of ARSACS cases have been described in 
Canadian patients, several cases of ARSACS have been 
described in other countries such as Japan, Italy, Bel-
gium, Tunisia, Spain and Turkey2,3,5. While the exact 
number of ARSACS patients described outside Canada 
is not known, approximately 30 mutations have been re-
ported in Quebec and non-Quebec patients6. The combi-
nation of spinocerebellar ataxia with spasticity, superior 
vermis atrophy and pontine linear hypointensities should 
prompt the diagnosis of ARSACS, which may be an un-
derdiagnosed condition outside Quebec7. ARSACS di-
agnosis is based on clinical manifestation, neuroimaging 
features and confirmed by demonstration of the dele-
tion in the sacsin gene, located on chromosome 13q13. 
Neuropathologic findings showed pyramidal degenera-
tion, cortical atrophy, atrophy of the superior cerebellar 
vermis and loss of motoneurons8.
The causal mutations in the SACS gene in individuals 
from northeastern Quebec include two founder muta-
tions, a single-base deletion at position 6594 (6594delT) 
and a 5254C>T nonsense mutation9. In a study of 164 al-
leles, 92.6% of individuals with ARSACS born in Quebec 
were homozygous for the deletion 6594delT and 3.7% 
were compound heterozygote for the common deletion 
and a missense 5254C>T mutation10. Several novel mu-
tations have now been described in individuals with AR-
SACS from Tunisia, Turkey, Italy, and Japan and previ-
ously reported in individuals who showed linkage to the 
13q11 locus. The phenotype observed in persons of Tuni-
sian heritage differs from that observed in Quebec-born 
individuals in the very low incidence of retinal networks 
of myelinated fibers and the later age of onset11. Grieco 
et al. described three new SACS mutations in two of the 
original six Italian families and in two individuals the 
phenotype was similar to that reported in Quebec-born 
individuals with ARSACS except for the absence of ret-
inal striations8. Similarly, our patients had no retinal al-
terations. Criscuolo et al. reported a new missense SACS 
mutation (7848C>T) in a Spanish family whose pheno-
type was similar to the earliest presentations associated 
with ARSACS, thus emphasizing the widespread occur-
rence of ARSACS-causing mutations around the world, 
with the highest incidence in the Mediterranean region12. 
The cardinal clinical features of ARSACS are delay in 
acquiring independent walk, frequent falls and gait in-
stability. Disease progression is slow. The major mani-
festations in the first two decades of life are: early onset 
ataxia, dysarthria, nystagmus, spasticity of the legs, bilat-
eral Babinski’s reflex, and hyperreflexia. Lower limb pe-
ripheral neuropathy can also be detected later. Distal at-
rophy, pes cavus and hammer toes are commonly seen 
as the disease progresses2,3,13. In some patients, fundos-
copy shows hypermyelination of fibers radiating from 
optic disc and embedding retinal vessels, a very pecu-
liar finding3. Curiously, cognitive function is preserved 
in ARSACS, although mild mental retardation and cog-
nitive decline have been occasionally reported. ARSACS 
usually appears between early childhood and preschool 
age (12 months old to 5.5 years old)2. Patients become 
wheelchair bound by the third or fourth decade of life3. 
There is no effective therapy for ARSACS but physical 
therapy and oral drug therapy such as baclofen can help 
control spasticity in the early phase of the disease and 
may prevent tendon shortening and joint contractures.
Imaging findings (brain CT or MRI) described in AR-
SACS include early and progressive atrophy of the supe-
rior cerebellar vermis. Interestingly, the inferior vermis 
remains thicker throughout the disease. In addition, 
global cerebral atrophy is common in later life. How-
ever, cerebral white matter remains preserved, even in 
more advanced disease1,14. Cervical and thoracic spinal 
cord thinning are occasionally reported3. Pontine linear 
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hypointensities in T2 and FLAIR images have been de-
scribed as a peculiar finding in this disease, but its actual 
meaning remains unclear1,7.
From a practical perspective, clinical and imaging 
features, early nerve conduction findings, and ocular 
signs are all together diagnostic of ARSACS14. Most AR-
SACS cases first reported by Bouchard et al.14 had been 
diagnosed as having cerebral palsy with spastic diplegia. 
Confusion with cerebral palsy and secondary spastic di-
plegia may in part explain the apparent low incidence of 
ARSACS in many parts of the world15. Troyer syndrome 
(also known as spastic paraplegia type 20) should be con-
sidered in the differential diagnosis of ARSACS. Troyer 
syndrome is characterized by spastic paraplegia with 
distal limb amyotrophy, dysarthria, and mild cerebellar 
signs. It has a higher frequency in the Amish popula-
tion than elsewhere in the world16. The apparent linkage 
of a limited number of cases from outside Quebec with 
the ARSACS locus on chromosome 13 otherwise sug-
gests that other recessive progressive combined pyra-
midal tract and cerebellar involvement syndromes could 
be part of an enlarged spastic ataxia group of spinocere-
bellar degenerations14. Further investigation for cerebral 
palsy or Troyer syndrome in our three patients seems 
unnecessary at the moment as the clinical and neuro-
imaging spectrum presented here is widely compatible 
with ARSACS. 
Our patients have major diagnostic criteria for clin-
ical diagnosis of ARSACS: early onset (between the age 
of 12 and 18 months) manifested by delayed walking re-
sulting from gait unsteadiness, progressive spastic ataxia 
of all limbs with paraplegia and atrophy of the supe-
rior cerebellar vermis and linear hypointensities in the 
pons on MRI. The combination of these features makes 
a probable diagnosis of ARSACS. Molecular genetic 
testing for the main mutation of ARSACS is not avail-
able in any center in Brazil. And testing for other SACS 
mutations, identified in populations outside of north-
eastern Quebec, are available for research purposes only.
In conclusion, this is the first documented report of 
clinical diagnosis of ARSACS in Brazil. We would like to 
stress the importance of promptly recognizing the dis-
ease when late-infantile low onset progressive ataxia as-
sociated with spasticity and typical neuroimaging fea-
tures are present. Additionally, cerebral palsy and Troyer 
syndrome should be considered in the differential diag-
nosis of early onset ataxia and spasticity. Imaging special-
ists should be familiar with typical neuroimaging features 
of ARSACS for more accurate diagnosis of recessive cer-
ebellar ataxias, and neurologists should have thorough 
understanding about the genetics of ARSACS in view 
of several descriptions of the syndrome outside Canada. 
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